Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of [18F]FLT PET/CT in Pediatric Solid Tumors
NCT03905538Phase 1Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Aug 2019
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluorothymidine F-18 in solid tumor, sponsored by UT Southwestern Medical Center. Primary endpoint: Correlation between change in [18F]FLT PET/CT and progression free and overall survival at 24 months. Planned start Aug 2019; status: withdrawn.
02
Drugs
fluorothymidine F-18
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03905538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905538.